leisure time -WSS

leisure time

author：entertainment 2025-10-01 15:28:19 - browse：82112

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： GOP inquiry over gain

WSS

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Update the Apgar Score to remove skin color

Cardiologists urge adding sexual orientation, gender identity to health records

FDA endorses new sterilization method for medical devices

Eating disorder hotline's move to chatbot carried cost for volunteers

Brazil's Jair Bolsonaro is barred from running for office until 2030

knowledge

leisure time

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

The simple reason for the increase in autism diagnosis

At least 13 dead in Texas as scorching temps continue

CVS is on a mission to consolidate health care. Will it work?

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare bonuses could stop drug shortages under Senate plan

Hepatitis C has a cure — but many Americans still lack access to it

Maisha Meds is a PBM, but don't call it that

How to save PrEP access — and even expand it

High breast density mammograms need follow

explore

Illumina to lay off 10% of research and development team

A pediatrician calls for Congress to pass the child tax credit deal

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Future doctors need a strong humanities education

Eating disorder hotline's move to chatbot carried cost for volunteers

Illumina to lay off 10% of research and development team

Wikipedia

explore

focus

leisure time